by @JTC_PALIdev | Nov 17, 2022 | Press Releases
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage...
by @JTC_PALIdev | Nov 15, 2022 | Press Releases
Carlsbad, CA, Nov. 15, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced a 1-for-50 reverse split of its common stock, par value...
by @JTC_PALIdev | Nov 14, 2022 | Press Releases
Carlsbad, CA, Nov. 14, 2022 — Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company” or “Palisade”), reported its...
by @JTC_PALIdev | Oct 11, 2022 | Press Releases
Board Appoints JD Finley to Interim Chief Executive OfficerCarlsbad, CA, Oct. 11, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced...
by @JTC_PALIdev | Sep 29, 2022 | Press Releases
Carlsbad, CA, Sept. 29, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American...
by @JTC_PALIdev | Sep 23, 2022 | Press Releases
Carlsbad, CA, Sept. 23, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under...
